17 Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment

Q: What does this research mean for the field?

Anti-CAIX/CD70 DFIR CAR-T cell therapy secreting an anti-PD-1/CTLA-4 bispecific antibody demonstrates robust antitumor efficacy, overcomes antigen heterogeneity, and mitigates on-target off-tumor toxicity in preclinical models of advanced clear cell renal cell carcinoma. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Yufei Wang

doi:10.1093/oncolo/oyag312.018

September 1, 2026The OncologistOpen Access

17 Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment

View Full Paper

Ask AI

Bookmark

Share

Key Points

To develop and evaluate a dual-targeted CAR-T cell therapy engineered to overcome tumor antigen heterogeneity, on-target off-tumor toxicity, and immunosuppression in advanced clear cell renal cell carcinoma.
Quantified CAIX and CD70 tumor density across disease stages using direct stochastic optical reconstruction microscopy (dSTORM) and immunohistochemistry.
Engineered affinity-tuned anti-CAIX/CD70 DFIR CAR-T cells armed with a secreted tetravalent anti-PD-1/CTLA-4 bispecific antibody.
Assessed cytotoxic persistence across repeated tumor challenges in vitro, screened scFv specificity via Retrogenix, and evaluated in vivo efficacy using a humanized orthotopic ccRCC mouse model.
Dual targeting of CAIX and CD70 expanded target tumor coverage across all stages, while the affinity-tuned G9 CAR moiety selectively killed high-CAIX tumor cells and spared low-expressing normal tissues.
The secreted tetravalent bispecific antibody demonstrated superior checkpoint inhibition compared to combined nivolumab and ipilimumab.
DFIR CAR-T cells produced robust, sustained cytotoxicity across repeated challenge rounds and showed enhanced in vivo tumor control in orthotopic ccRCC mouse models without off-target cross-reactivity.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Preclinical study demonstrates enhanced tumor control by dual-targeting CAR-T cells in clear cell renal cell carcinoma models, suggesting a strategy to overcome immunosuppression.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yufei Wang (2026) studied this question.

synapsesocial.com/papers/6a993653636c6408cfa7f69b https://doi.org/10.1093/oncolo/oyag312.018

View Full Paper

Ask AI

Bookmark

Share

17 Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

17 Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading